Hanmi Pharm ‘confirms the effect of SERM+Vitamin D combo’

Including its RaboneD Cap.

The big data-based study published in International Osteoporosis Foundation’s official journal

Hanmi Pharmaceutical announced on the 27th that the results of big data-based research on 'SERM+Vitamin D combination drugs', including its own ‘RaboneD’, were published in the SCI-level international journal, 'Osteoporosis International'.

 

RaboneD is an osteoporosis treatment developed by Hanmi Pharmaceutical that combines vitamin D with the SERM class raloxifene.

 

The study compared the efficacy of selective estrogen receptor modulator (SERM) + vitamin D combination and SERM alone in 2,885 patients diagnosed with osteoporosis using insurance claims data from the National Health Insurance Service from 2017 to 2019.

 

Sang-Min Kim, Professor of Orthopedic Surgery at Korea University College of Medicine Guro Hospital, Seong-Eun Byun, Professor of Orthopaedic Surgery, CHA Bundang Medical Center, and Hanmi Pharm’s data science team participated in the study.

 

Study results showed that the SERM+Vitamin D combination significantly lowered the risk of osteoporotic fractures by approximately 23% compared with SERM alone, and the combination reduced the risk of hip fracture by approximately 75% compared with SERM alone.

 

This is the first real-world, data-driven study to analyze the fracture reduction effect of a SERM+vitamin D combination compared with SERM alone.

 

The results showed that the SERM+Vitamin D combination was effective in reducing the risk of hip fracture as well as osteoporotic fractures compared to SERM alone.

 

Professor Sang-Min Kim, said, "We found that the risk of osteoporotic fracture was significantly lower in the SERM+Vitamin D administered group compared with the monotherapy group in women with osteoporosis aged 50 years and older in Korea.

 

The results suggest that the SERM+Vitamin D combination may be a viable option for postmenopausal women with a relatively low fracture risk.” Professor Seong-Eun Byun, said, “SERM class osteoporosis treatments not only improve bone density and lipid profiles, but also act like antiestrogen in the uterus and breast, so there is less concern about the risk of endometrial and breast cancer.

 

As Vitamin D is an important factor that controls the whole body calcium homeostasis and is known to be necessary for bone health, several guidelines recommend adequate intake of vitamin D for patients with osteoporosis." An Hanmi Pharmaceutical official said, "As a typical chronic disease, the number of osteoporotic fractures has been continuously increasing with Korea’s entry into a super-aged society.

 

Therefore, we expect the results of this study to broaden the treatment options for doctors and patients.”